<DOC>
	<DOCNO>NCT01264497</DOCNO>
	<brief_summary>The purpose study determine whether TH9507 , stabilize analogue growth hormone-releasing factor ( GRF ) , would effect insulin sensitivity control diabetes patient type 2 diabetes .</brief_summary>
	<brief_title>Safety Study TH9507 Subjects With Stable , Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male postmenopausal surgically sterilize female subject , 50 year age old ; Documented diagnosis type 2 diabetes define American Diabetes Association ; Diagnosis type 2 diabetes least 3 month screen ; Subjects stable diabetes treatment regimen ( receive oral hypoglycemics without insulin ) least 2 month screen ; Screening prerandomization glycosylated hemoglobin ( HbA1c ) &lt; 10.0 % , accord central laboratory ; Body mass index ( BMI ) 25 38 kg/m2 Subjects willing perform specify home blood glucose monitoring comply study protocol requirement ; Signed informed consent . Serum creatinine &gt; 2 mg/dL ; Fasting triglycerides &gt; 1000 mg/dL ; Albuminuria &gt; 200 mg/24 hour ; Positive mammography ( female ) prostatespecific antigen ( PSA ) prostate examination cancer ( male ) ; Use oral parenteral glucocorticoid 30 day screen ; Use experimental market growth hormone , growth hormone secretagogues , insulinlike growth factor1 ( IGF1 ) , insulinlike growth factor bind protein3 ( IGFBP3 ) previous 6 month ; Subjects two severe hypoglycemia episode within past 6 month , hospitalization emergency room visit due poor glycemic control within past 6 month . Similarly , leadin period , subject one severe hypoglycemic episode hospitalization emergency room visit due poor glycemic control exclude randomization ; History presence active concomitant condition disease ( e.g. , myocardial infarction , poorly control hypertension , thyroid disease , rheumatoid arthritis , seizure disorder , diabetic neuropathy , diabetic retinopathy [ except subject microaneurysms fundus examination ] ) would interfere protocol conduct endpoint measurement ; Subjects major surgical operation 30 day screen ; Subjects know hypopituitarism , history pituitary tumor/surgery , head irradiation , severe head trauma ; Current cancer history cancer , except nonmelanomatous skin cancer ; Subjects active infection body site history severe infection ( require oral parenteral treatment ) 30 day screen ; Subjects clinically significant abnormality screen laboratory evaluation ( unless discuss approve medical monitor ) ; Subjects allergy synthetic growth hormone product excipients ; Subjects previously receive growth hormone clinical trial ; Participation trial experimental drug device within 90 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>